Zhejiang Taimei Medical Technology Co (FRA:A2V) ROC (Joel Greenblatt) %: -138.71% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:A2V Zhejiang Taimei Medical Technology Co Ltd FRA:A2V
11 GF Score
Price €0.60
! 4 Warning Signs
View Full Analysis

What is Zhejiang Taimei Medical Technology Co ROC (Joel Greenblatt) %?

Zhejiang Taimei Medical Technology Co FRA:A2V +1.69% 11 ROC (Joel Greenblatt) % is -138.71% as of Dec. 2025. GuruFocus rates FRA:A2V with a GF Score™ of 11/100. The stock has 4 warning signs investors should review. Among 665 Healthcare Providers & Services companies, Zhejiang Taimei Medical Technology Co ranks worse than 84.06% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Zhejiang Taimei Medical Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -138.71%.

The historical rank and industry rank for Zhejiang Taimei Medical Technology Co's ROC (Joel Greenblatt) % or its related term are showing as below:

FRA:A2V' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -559.15   Med: -433.53   Max: -156.97
Current: -156.97

During the past 5 years, Zhejiang Taimei Medical Technology Co's highest ROC (Joel Greenblatt) % was -156.97%. The lowest was -559.15%. And the median was -433.53%.

FRA:A2V's ROC (Joel Greenblatt) % is ranked worse than
84.06% of 665 companies
in the Healthcare Providers & Services industry
Industry Median: 12.48 vs FRA:A2V: -156.97

Zhejiang Taimei Medical Technology Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Zhejiang Taimei Medical Technology Co  (FRA:A2V) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Zhejiang Taimei Medical Technology Co ROC (Joel Greenblatt) % Related Terms


Zhejiang Taimei Medical Technology Co ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Zhejiang Taimei Medical Technology Co's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Taimei Medical Technology Co ROC (Joel Greenblatt) % Chart

Zhejiang Taimei Medical Technology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
-433.52 -424.62 -542.72 -572.95 -165.11

Zhejiang Taimei Medical Technology Co Semi-Annual Data
Dec21 Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial 0.00 -845.48 -236.38 -149.17 -138.71

FRA:A2V vs VEEV, BTSG, HQY: ROC (Joel Greenblatt) % Comparison

For the Health Information Services subindustry, Zhejiang Taimei Medical Technology Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Taimei Medical Technology Co ROC (Joel Greenblatt) % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Zhejiang Taimei Medical Technology Co's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Zhejiang Taimei Medical Technology Co's ROC (Joel Greenblatt) % falls into.


FRA:A2V
11GF Score
Zhejiang Taimei Medical Technology Co Ltd FRA:A2V
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Taimei Medical Technology Co ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(19.917 + 0 + 10.424) - (20.55 + 0 + 8.502)
=1.289

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(21.783 + 0 + 9.281) - (24.366 + 0 + 8.359)
=-1.661

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Zhejiang Taimei Medical Technology Co for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-5.126/( ( (3.395 + max(1.289, 0)) + (2.707 + max(-1.661, 0)) )/ 2 )
=-5.126/( ( 4.684 + 2.707 )/ 2 )
=-5.126/3.6955
=-138.71 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -138.71% mean?
Zhejiang Taimei Medical Technology Co (FRA:A2V) has a ROC (Joel Greenblatt) % of -138.71% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Zhejiang Taimei Medical Technology Co and its competitors. According to the industry distribution chart, Zhejiang Taimei Medical Technology Co ranks #559 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 84.1%.
Is Zhejiang Taimei Medical Technology Co's ROC (Joel Greenblatt) % too high?
Zhejiang Taimei Medical Technology Co's current ROC (Joel Greenblatt) % is -138.71%. Based on the distribution chart, Zhejiang Taimei Medical Technology Co ranks #559 out of 665 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Zhejiang Taimei Medical Technology Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Taimei Medical Technology Co's ROC (Joel Greenblatt) % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Zhejiang Taimei Medical Technology Co ranks #559 out of 665 companies for ROC (Joel Greenblatt) %. This places Zhejiang Taimei Medical Technology Co in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 12.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median ROC (Joel Greenblatt) % among Healthcare Providers & Services companies is 12.48, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Zhejiang Taimei Medical Technology Co and its competitors. For the Healthcare Providers & Services industry, the median ROC (Joel Greenblatt) % is 12.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Taimei Medical Technology Co's current ROC (Joel Greenblatt) % is -138.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Taimei Medical Technology Co stock overvalued right now?
Zhejiang Taimei Medical Technology Co (FRA:A2V) has a current ROC (Joel Greenblatt) % of -138.71%. The current ROC (Joel Greenblatt) % is -138.71%. Zhejiang Taimei Medical Technology Co's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Zhejiang Taimei Medical Technology Co (FRA:A2V), the current ROC (Joel Greenblatt) % is -138.71% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zhejiang Taimei Medical Technology Co Business Description

Other Exchanges 02576:Hong Kong
Address 36 Changsheng South Road, 3rd Floor, Building 9, Smart Industry Innovation Park, Zhejiang Province, Jiaxing, CHN
Zhejiang Taimei Medical Technology Co Ltd is a digital solution provider focused on the pharmaceutical and medical device industry in China. It designs and delivers industry-specific software and digital services that facilitate research and development (R&D) and the commercialization of pharmaceuticals and medical devices. The software it offers is cloud-based, allowing users to access it from various devices at any time over the internet, without the need for software installation and maintenance on their devices. It has a geographical presence in Mainland China, the United States, Singapore, Korea, and Others.
11GF Score

Get the complete analysis for FRA:A2V

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60
Price